Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jon Grant, University of Chicago
ClinicalTrials.gov Identifier:
NCT00513019
First received: August 7, 2007
Last updated: August 6, 2013
Last verified: August 2013
  Purpose

The goal of the proposed study is to evaluate the comparative efficacy of Lamictal (lamotrigine) to placebo in neurotic excoriation. Thirty subjects with neurotic excoriation will receive 12 weeks of double-blind treatment with Lamictal (lamotrigine) or matching placebo. The hypothesis to be tested is that Lamictal (lamotrigine) will be more effective than placebo in patients with neurotic excoriation. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.


Condition Intervention Phase
Neurotic Excoriation
Pathologic Skin Picking
Psychogenic Excoriation
Dermatillomania
Drug: Lamictal (lamotrigine)
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Study of Lamictal in Neurotic Excoriation

Resource links provided by NLM:


Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) Will be the Primary Outcome Measure [ Time Frame: beginning and at each visit until the end of their participation in the study (12-weeks); investigator rated. Note: Reported mean and standard deviation is the final reported data point. ] [ Designated as safety issue: No ]
    The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) was the primary outcome measure - severity of illness. The NE-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity).


Enrollment: 35
Study Start Date: August 2007
Study Completion Date: September 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Lamictal (lamotrigine)
Drug: Lamictal (lamotrigine)
once daily from beginning to end of study. Dosage varies.
Other Name: lamotrigine
Placebo Comparator: 2
Placebo
Drug: Placebo
daily

Detailed Description:

The study will consist of 12 weeks of double-blind treatment with Lamictal (lamotrigine) compared to placebo (1:1) in 30 subjects with neurotic excoriation.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. men and women age 18-65;
  2. current diagnosis of neurotic excoriation.

Exclusion Criteria:

  1. unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination;
  2. history of seizures;
  3. myocardial infarction within 6 months;
  4. current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
  5. a need for medication other than Lamictal with possible psychotropic effects or unfavorable interactions with Lamictal;
  6. clinically significant suicidality;
  7. lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder;
  8. current or recent (past 3 months) DSM-IV substance abuse or dependence;
  9. illegal substance use within 2 weeks of study initiation;
  10. initiation of psychotherapy or behavior therapy from a mental health professional within 3 months prior to study baseline;
  11. previous treatment with Lamictal (lamotrigine);
  12. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline;
  13. current treatment with an anti-epileptic medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00513019

Locations
United States, Minnesota
Ambulatory Research Center
Minneapolis, Minnesota, United States, 55454
Sponsors and Collaborators
University of Chicago
Investigators
Principal Investigator: Jon E Grant, M.D. University of Minnesota - Clinical and Translational Science Institute
  More Information

No publications provided

Responsible Party: Jon Grant, Professor of Psychiatry, University of Chicago
ClinicalTrials.gov Identifier: NCT00513019     History of Changes
Other Study ID Numbers: 0703M03384
Study First Received: August 7, 2007
Results First Received: March 1, 2012
Last Updated: August 6, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Chicago:
Neurotic Excoriation
Pathologic Skin Picking
Psychogenic Excoriation

Additional relevant MeSH terms:
Dermatitis
Self-Injurious Behavior
Skin Diseases
Behavioral Symptoms
Lamotrigine
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers

ClinicalTrials.gov processed this record on August 28, 2014